# Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission

> **NCT00458523** · PHASE2 · COMPLETED · sponsor: **Leeds Cancer Centre at St. James's University Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **GENETIC:** fluorescence in situ hybridization
- **GENETIC:** mutation analysis
- **OTHER:** flow cytometry

## Key facts

- **NCT ID:** NCT00458523
- **Lead sponsor:** Leeds Cancer Centre at St. James's University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** 2008-02
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458523, "Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00458523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*